Unknown Ingredients: Patches made from supplements might have unsafe or hidden additives
Case Rep
In people, the evidence is much more limited
It is currently in Phase 3 clinical trials
GLP-1 inhibits intestinal contractions through mechanisms that may involve the central nervous system via vagal pathways or direct action on central receptors [24], as well as the enteric nervous system by modulating neurotransmission through presynaptic receptors affecting nitric oxide release [25,26]
GLP-1 receptors are present in the brain, cerebral blood vessels, pancreas, heart, gastrointestinal tract, adipose tissue, kidney, and muscles, and consequently affect a variety of systems and processes [38,39,40]